sintilimab
eli lilly
['nsclc', 'sclc']
#asco22 dr. fuming qiu presents virtually the results of neoscore comparing 2 vs 3 cycles of neoadjuvant chemo-immunotherapy for resectable nsclc. mpr and pcr rates favor 3 over 2 cycles (n=60, trial stopped early) 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him